Global Finance News
01 Nov 2026, 11:49
Bristol Myers Squibb Raises 2026 Revenue Outlook as Growth Portfolio Sales Increase 12%
Bristol Myers Squibb (NYSE: BMY) reported third-quarter 2026 revenue of $13.1 billion, up 7% year over year, supported by continued double-digit growth across its newer medicines portfolio.
Growth Portfolio revenue increased 12% to $7.7 billion, led by Opdivo Qvantig, Breyanzi, Reblozyl, Camzyos and Opdualag. Legacy Portfolio revenue rose 1% to $5.4 billion, with Eliquis growth offsetting continued generic pressure across other mature products.
U.S. revenue increased 9% to $9.1 billion, while international revenue rose 3% to $4.0 billion, or 4% excluding currency effects.
GAAP EPS was $1.05, down from $1.08 a year earlier, while non-GAAP EPS declined 17% to $1.35. Both figures included a $0.58-per-share negative net impact from acquired in-process research and development charges and licensing income, compared with a $0.20 impact in the prior-year quarter.
Bristol Myers raised its full-year 2026 revenue forecast to $49.75 billion-$50.25 billion from the previous $49.0 billion-$50.0 billion range, citing broad-based portfolio momentum. However, non-GAAP EPS guidance was revised down to $6.35-$6.55 from $6.75-$7.00, largely reflecting a much larger expected impact from acquired IPR&D and licensing activity.
The company continues to expect worldwide Eliquis revenue to grow 20%-25% in 2026. Recent pipeline progress, including the approval of Zenbexus for multiple myeloma, also supports Bristol Myers’ effort to offset future erosion in its legacy portfolio with newer growth products.
Bristol Myers Squibb (NYSE: BMY) reported third-quarter 2026 revenue of $13.1 billion, up 7% year over year, supported by continued double-digit growth across its newer medicines portfolio.
Growth Portfolio revenue increased 12% to $7.7 billion, led by Opdivo Qvantig, Breyanzi, Reblozyl, Camzyos and Opdualag. Legacy Portfolio revenue rose 1% to $5.4 billion, with Eliquis growth offsetting continued generic pressure across other mature products.
U.S. revenue increased 9% to $9.1 billion, while international revenue rose 3% to $4.0 billion, or 4% excluding currency effects.
GAAP EPS was $1.05, down from $1.08 a year earlier, while non-GAAP EPS declined 17% to $1.35. Both figures included a $0.58-per-share negative net impact from acquired in-process research and development charges and licensing income, compared with a $0.20 impact in the prior-year quarter.
Bristol Myers raised its full-year 2026 revenue forecast to $49.75 billion-$50.25 billion from the previous $49.0 billion-$50.0 billion range, citing broad-based portfolio momentum. However, non-GAAP EPS guidance was revised down to $6.35-$6.55 from $6.75-$7.00, largely reflecting a much larger expected impact from acquired IPR&D and licensing activity.
The company continues to expect worldwide Eliquis revenue to grow 20%-25% in 2026. Recent pipeline progress, including the approval of Zenbexus for multiple myeloma, also supports Bristol Myers’ effort to offset future erosion in its legacy portfolio with newer growth products.
